Table 2

Clinical characteristics of patients with Parkinson's disease (PD) or multiple system atrophy (MSA) with and without sleep complaints

PD patients with sleep complaintsPD patients without sleep complaintsMSA patients with sleep complaintsMSA patients without sleep complaints
Values are presented as mean (SD) or percentages.
*p<0.05 when compared with PD patients with sleep complaints, **p<0.05 when compared with PD patients without sleep complaints.
UPDRS, Unified Parkinson's diseaserating scale; MMSE, mini mental state examination; CES-D, Center for Epidemiological Studies depression scale.
Percentage514970*30
Age (years)66.2 (7.9)64.2 (9.7)67.5 (7.8)67 (10.2)
Men (%)58.066062.523.53
Disease duration (years)8 (4.5)6 (4.1)6.2 (3.2)4.7 (3.6)
Hoehn and Yahr score2.34 (0.83)1.98 (0.65)3.32 (1.38)3.03 (1.34)
UPDRS-III score31.13 (13.11)29.18 (13.87)50.33 (19.64)43.29 (17.17)
Schwab and England score70.32 (22.13)75.67 (15.69)40.51 (24.7)44.12 (26.71)
MMSE score27.26 (2.64)27.7 (2.07)25.78 (3.79)26.53 (2.89)
Autonomic failure (%)41.9427.599582.35
CES-D score14.04 (10.37)11.9 (10.59)21.06 (11.39)18.71 (9.1)
Antidepressant use (%)35.4817.2442.552.94
Daily levodopa (mg)626.61 (367.24)512.5 (349.82)565.63 (471.48)484.56 (434.22)
Duration of levodopa therapy (years)6.8 (4.01)**3.99 (3.49)4 (3.66)2.71 (3.34)
Dopamine agonist use (%)74.2**37.832.5*47.1
Amantadine use (%)12.917.2411.827.5